SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): May 7, 2009
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1301
Harbor Bay Parkway
Alameda,
California 94502
(Address
of principal executive offices)
(510)
521-3390
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Statements made in this Report that
are not historical facts may constitute forward-looking statements that are
subject to risks and uncertainties that could cause actual results to differ
materially from those discussed. Such risks and uncertainties include
but are not limited to those discussed in this report and in BioTime's Annual
Report on Form 10-K filed with the Securities and Exchange Commission. Words
such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,” “believes,”
“seeks,” “estimates,” and similar expressions identify forward-looking
statements.
Section
7 - Regulation FD
Item
7.01 - Regulation FD Disclosure
Section
9 - Financial Statements and Exhibits
Item
9.01 - Financial Statements and Exhibits.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press
Release Dated May 7,
2009
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
BIOTIME,
INC.
|
|
|
Date: May
7, 2009
|
By
/s/ Steven A.
Seinberg
|
|
Chief
Financial Officer
|
|
3
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press
Release Dated May 7, 2009
|
|
4
Exhibit
99.1
|
BioTime,
Inc.
|
1301
Harbor Bay Parkway
|
|
|
Alameda,
CA 94502
|
||
|
Tel:
510-521-3390
|
||
|
Fax:
510-521-3389
|
||
|
www.biotimeinc.com
|
||
|
www.embryome.com
|
BioTime
CEO Dr. Michael West to Present at World Stem Cells &
Regenerative
Medicine Congress 2009 and Discuss New Cell Lines with
Cartilage-Forming
Potential
ALAMEDA, CA, May 7, 2009 – BioTime, Inc. (OTCBB: BTIM)
Chief Executive Officer Michael West, Ph.D. will deliver a presentation on May
14, 2009 at the World
Stem Cells and Regenerative Medicine Congress meeting in
London. Dr. West’s presentation is titled “Opportunities and
Challenges of Commercializing Stem Cell Research.”
This
year’s conference will focus on a broad array of topics related to stem cell
research, including the biology, medicine, applications, regulation, and
business of Stem Cells. Dr. West’s presentation will include a description of
BioTime’s stem cell research programs that are focused on opportunities for
near-term revenues in the development and marketing of cell lines.
Dr.
West will also discuss for the first time data relating to progenitor
cell lines, produced using BioTime’s ACTCellerate™ technology, that exhibit
markers for becoming cartilage cells. Embryonic progenitor cells that
produce cartilage might have a use in the development of treatments for
orthopedic diseases such as arthritis and degenerative diseases of the
spine.
Dr.
West’s presentation will be available online at http://www.biotimeinc.com/
on May 13, 2009.
About
BioTime, Inc.
BioTime,
headquartered in Alameda, California, is a biotechnology company focused on the
emerging field of regenerative medicine. BioTime's lead product, Hextend®, is a
blood plasma expander used in surgery, emergency trauma treatment and other
applications. Hextend is manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive
licensing agreements.
BioTime
markets its stem cell research products through its wholly owned subsidiary
Embryome Sciences,
Inc. which is developing new medical and research products using
embryonic stem cell technology. Additional information about BioTime
can be found on the web at www.biotimeinc.com.
Hextend®,
ESpyTM, and
ESpanTM, are
trademarks of BioTime, Inc.
Forward-Looking
Statements
Statements
pertaining to future financial and/or operating results, future growth in
research, technology, clinical development and potential opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also
be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, uncertainty
in the results of clinical trials or regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with the
many uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or obligation to
update these forward-looking statements.
Contact:
BioTime,
Inc.
Judith
Segall
jsegall@biotimemail.com
510-521-3390,
Ext 301
To
receive ongoing BioTime corporate communications, please click on the following
link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0